A Phase 1A Dose Escalation and Phase 1B Expansion Study to Evaluate the Safety and Tolerability of ETC-1907206 in Combination With Dasatinib in Advanced Haematologic Malignancies
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Dasatinib (Primary) ; ETC-1907206 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; Pharmacokinetics
- 23 Oct 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 20 May 2018 Status changed from not yet recruiting to recruiting.
- 15 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Apr 2018.